Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

NCT04892264 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Low/slow accrual - did not proceed to Phase 2

Conditions

Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

BIOLOGICAL: Belantamab Mafodotin
BIOLOGICAL: Daratumumab
DRUG: Dexamethasone
DRUG: Lenalidomide
OTHER: Quality-of-Life Assessment
PROCEDURE: Biospecimen Collection
PROCEDURE: Skeletal Survey X-Ray
PROCEDURE: Low Dose Computed Tomography of the Whole Body
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy

Sponsor

Mayo Clinic